
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical reported full-year 2025 revenue of approximately $71.6 million, representing an 11% increase from $64.3 million in 2024 and aligning with the company’s revised guidance. The company also improved its net cash use sequentially to approximately $5.1 million, down from $6.2 million in the third quarter, indicating enhanced financial efficiency. Looking ahead, management has provided a 2026 revenue guidance of $80 million to $85 million, suggesting renewed commercial momentum through deeper penetration in burn and trauma centers as well as a broadened product portfolio.
Bears say
AVITA Medical's financial outlook has weakened, leading to a downward revision of revenue expectations and a target valuation decrease from $14.0 to $10.0. The company's net loss remained unchanged at $11.6 million for the latest period, reflecting a loss per share of $0.38, slightly improving from the prior year's loss of $0.44 per share. Given the reliance on a single product, the RECELL system, and a limited international marketing strategy, concerns about sustainable growth persist.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares